
What Medicaid Cuts Would Do to My Rural Hospital
In 2021, a pileup involving dozens of cars on that highway brought more than 30 patients to our two-bed emergency room, where our small staff sprang into action to stabilize the most seriously injured patients. Our hospice team met with the family of a child who died at the scene of the accident. One fatality is too many, but without our hospital, there surely would have been more.
Nearly 200 rural hospitals have closed in the past two decades — the result of financial strain and staff shortages — but my hospital has been able to keep its doors open through sheer perseverance. Now, however, Congress is considering cuts to Medicaid that could wreak havoc on rural America's fragile health care system. I worry about our future.
One proposal would reduce the portion of Medicaid dollars the federal government gives to states, such as Colorado, that have expanded Medicaid eligibility. Another would strictly cap federal payments to states, regardless of geographic differences in the cost of care.
Cuts to Medicaid could hurt the finances of hospitals across the country, but rural hospitals will be particularly affected. This is because rural patients are more likely to have health coverage from the government than from commercial insurers. (Nearly three-quarters of our revenue, for example, is from Medicaid and Medicare.) These programs are essential, but, unlike commercial insurance, they don't always cover the total cost of care, which has been rising as drugs and supplies become more expensive. We also serve fewer patients than big city hospitals but still have fixed costs to stay operational. The result is that we run on minimal or negative operating margins.
According to the Colorado Rural Health Center, the state's nonprofit office of rural health, roughly half of my state's rural hospitals are operating in the red. Yet we're relatively lucky: Colorado's decision to expand Medicaid in 2014 has been a lifeline for us because it reduces the number of patients we see who can't pay.
Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.
Thank you for your patience while we verify access.
Already a subscriber? Log in.
Want all of The Times? Subscribe.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
an hour ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.


USA Today
7 hours ago
- USA Today
Saquon Barkley among NFL stars who will join President Trump's council on Sports Nutrition
Eagles running back Saquon Barkley will join Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor on President Trumps Council on Sports, Fitness, and Nutrition.' Saquon Barkley is a son, a fantastic father, the NFL's Offensive Player of the Year winner, and now a member of President Donald Trump's administration. In a move that will revive a standard from the Reagan, Clinton, and Bush era, Barkley will join Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor on President Trump's Council on Sports, Fitness, and Nutrition.' According to the Washington Post, President Trump on Thursday announced that the presidential fitness test, a hallmark of American physical education programs, will be making a comeback in public schools. The assessment was retired and replaced by a fitness program under the Obama administration. The presidential fitness test was initiated in the 1950s by a council established by President Dwight D. Eisenhower that was directed to improve the physical fitness of American youths, in response to fears they were falling behind their European counterparts when it came to athleticism. The project is an alternative way to get anti-obesity drugs to Medicare and Medicaid patients, after the administration said in April that neither program would cover GLP-1s for weight loss. In doing so, it scrapped a 2024 Biden administration proposal for the programs to start covering GLP-1s for patients with obesity. Several high-profile athletes — all of whom have existing ties to Trump — attended the ceremony and will serve on the President's Council on Sports, Fitness and Nutrition. The attendees included professional golfer Bryson DeChambeau, who will chair the council; controversial National Football League kicker Harrison Butker; World Wrestling Entertainment mainstay Paul 'Triple H' Levesque; golfer Annika Sorenstam; and football Hall of Famer Lawrence Taylor. The Eagles running back wasn't in attendance, but will be joined by golfers Jack Nicklaus, Nelly Korda, and Gary Player (who was also awarded the Medal of Freedom alongside Sorenstam); Tony Romo, Nick Bosa, and Barkley; legendary hockey player Wayne Gretzky; and baseball player Mariano Rivera. The list also includes NFL Commissioner Roger Goodell, whom Trump repeatedly scrutinized during his first presidential term. Barkley was criticized during the off-season for spending time with President Trump on a golf outing prior to the Eagles' ring celebration.


Business Upturn
8 hours ago
- Business Upturn
SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS
IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States. We are proud to share that we have been included in the Medicare fee schedule, allowing us to offer national Medicare coverage along with our new partnerships with CareSource and HealthPartners. The SmartVascular Dx test provides a significant clinical advantage by accurately detecting vascular inflammation, a crucial factor in assessing cardiovascular risk. In a healthcare landscape increasingly focused on preventive strategies, this test supports early intervention, aligning seamlessly with the commitment to proactive healthcare in the region. We encourage physicians in the northeastern United States to seize this opportunity to offer the SVDx test to their patients. By identifying vascular risks earlier, healthcare providers can implement timely interventions, ultimately saving lives and improving health outcomes. Furthermore, we are excited to announce our partnership with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact [email protected] 866.299.8998 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash